Global Vaccines Market 2024-2028

Description

List of Tables

The vaccines market is forecasted to grow by USD 56.39 bn during 2023-2028, accelerating at a CAGR of 13.83% during the forecast period. The report on the vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased funding for vaccine development and new vaccine launches, need for novel vaccines for chronic infections, and increasing use of adjuvants in vaccines.

Technavio's vaccines market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	12.85%
CAGR	13.83%
Incremental Value	$56.39bn

By Type

Human vaccine
Animal vaccine

By End-user

Hospitals
Clinics

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the development of nanoparticle vaccines as one of the prime reasons driving the vaccines market growth during the next few years. Also, increase in awareness of vaccine-preventable diseases among travelers and advancement in vaccine delivery system will lead to sizable demand in the market.

The report on the vaccines market covers the following areas:

Vaccines market sizing
Vaccines market forecast
Vaccines market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading vaccines market vendors that include Astellas Pharma Inc., Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novavax Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Valneva SE, and AstraZeneca PLC. Also, the vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR40041

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

4.1 Global vaccines market 2018 - 2022
4.2 Type Segment Analysis 2018 - 2022
4.3 End-user Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition

6 Market Segmentation by Type

6.1 Market segments
6.2 Comparison by Type
6.3 Human vaccine - Market size and forecast 2023-2028
6.4 Animal vaccine - Market size and forecast 2023-2028
6.5 Market opportunity by Type

7 Market Segmentation by End-user

7.1 Market segments
7.2 Comparison by End-user
7.3 Hospitals - Market size and forecast 2023-2028
7.4 Clinics - Market size and forecast 2023-2028
7.5 Market opportunity by End-user

8 Customer Landscape

8.1 Customer landscape overview

9 Geographic Landscape

9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 UK - Market size and forecast 2023-2028
9.9 Germany - Market size and forecast 2023-2028
9.10 Canada - Market size and forecast 2023-2028
9.11 China - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

12.1 Vendors covered
12.2 Market positioning of vendors
12.3 Astellas Pharma Inc.
12.4 AstraZeneca PLC
12.5 Bavarian Nordic AS
12.6 Bharat Biotech Ltd.
12.7 BrightPath Biotherapeutics Co. Ltd.
12.8 CSL Ltd.
12.9 Daiichi Sankyo Co. Ltd.
12.10 Emergent BioSolutions Inc.
12.11 GlaxoSmithKline Plc
12.12 Gradalis Inc.
12.13 Johnson and Johnson Services Inc.
12.14 Merck KGaA
12.15 Novavax Inc.
12.16 Pfizer Inc.
12.17 Sanofi SA

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
13.3 Currency conversion rates for US$
13.4 Research methodology
13.5 List of abbreviations